Sandra Calvin Sells 925 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 925 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $18.94, for a total value of $17,519.50. Following the completion of the sale, the chief accounting officer now owns 54,002 shares of the company’s stock, valued at $1,022,797.88. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sandra Calvin also recently made the following trade(s):

• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $17.22, for a total value of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.30, for a total value of $221,247.00.

Travere Therapeutics Price Performance

TVTX stock opened at $20.81 on Friday. The business’s fifty day moving average price is $18.28 and its 200 day moving average price is $14.79. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $20.89. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The company has a market capitalization of $1.62 billion, a PE ratio of -4.57 and a beta of 0.70.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.01. The company had revenue of $62.90 million during the quarter, compared to the consensus estimate of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. Travere Therapeutics’s revenue was up 69.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.17) EPS. On average, sell-side analysts anticipate that Travere Therapeutics, Inc. will post -3.92 EPS for the current year.

Institutional Investors Weigh In On Travere Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. R Squared Ltd purchased a new stake in shares of Travere Therapeutics during the fourth quarter worth $53,000. CWM LLC grew its stake in Travere Therapeutics by 158.5% during the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after purchasing an additional 3,065 shares in the last quarter. DRW Securities LLC purchased a new stake in Travere Therapeutics during the 2nd quarter worth about $95,000. Quarry LP acquired a new stake in Travere Therapeutics in the 3rd quarter valued at about $105,000. Finally, Forefront Analytics LLC boosted its stake in shares of Travere Therapeutics by 10.2% in the 2nd quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after buying an additional 1,237 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Travere Therapeutics in a research report on Friday, January 10th. They set an “overweight” rating on the stock. Canaccord Genuity Group decreased their target price on shares of Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a report on Monday, September 30th. Scotiabank increased their price target on shares of Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Wells Fargo & Company raised shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $9.00 to $27.00 in a research report on Monday, October 21st. Finally, Guggenheim increased their price objective on Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.